MTOR and endometrial cancer: mTOR inhibitor temsirolimus has been evaluated as a single agent in heavily pretreated patients with advanced or recurrent endometrial cancer with 9% partial responses, whereas pilaralisib showed 6% ORR in patients with advanced or recurrent endometrial cancer with up to two prior lines of treatment [46,47].